<DOC>
	<DOCNO>NCT01263080</DOCNO>
	<brief_summary>Multicentre randomise double-blind , placebo-controlled 2x2 factorial trial investigate effect add mirtazapine folic acid exist therapy patient schizophrenia</brief_summary>
	<brief_title>Evaluation Mirtazapine Folic Acid Schizophrenia :</brief_title>
	<detailed_description>The combination mirtazapine plus antipsychotic potentially offer considerable benefit patient schizophrenia . Folic acid promise adjunctive therapy schizophrenia may also provide benefit patient mental disorder . Furthermore effect folic acid may affect genotype . The trial investigate effect add mirtazapine effect add folic acid treatment schizophrenia . At randomisation , patient separately randomise mirtazapine placebo folic acid placebo . Randomised , double-blind , placebo-controlled 2x2 factorial trial 12-week follow-up .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1 . Inpatients outpatients age 18 70 year ; 2 . Meet DSMIV criterion schizophrenia ; 3 . Signed informed consent form patient legally acceptable representative ; 4 . PANSS total score &gt; =60 least one item P1 , P2 , P3 , P5 P6 &gt; =4 ensure subject current active psychotic symptom i.e . hallucination , delusion , think disorder ; 5 . Subjects currently take effective dose antipsychotic ; 6 . Women must agree practice effective method birth control sexually active entry throughout study . 1 . Meet DSMIV Axis I disorder ; 2 . Meet DSMIV criterion substance abuse dependence ; 3 . Have treatmentresistant 2 kind antipsychotics sufficient dosage least 4 week , require clozapine treatment , receive clozapine treatment within 1 month prior randomization ; 4 . Subjects actively suicidal judge clinically risk serious suicidal violent behavior opinion investigator ; 5 . Have serious unstable medical illness ( e.g. , cardiovascular disease , neurologic , hematologic , renal , hepatic , immunologic , endocrine , systemic illness ) , clinically significant abnormality laboratory test ECG indicate severe medical condition ; 6 . Have receive electroconvulsive therapy within 28 day randomization ; 7 . Have receive long act antipsychotic within 1 treatment cycle randomization ; 8 . Have receive antidepressant within 14 day , receive MAOIs within 4 week randomization require antidepressive treatment ; 9 . History prostatic hypertrophy dysuria ; 10 . History narrowangle glaucoma elevation intraocular pressure ; 11 . Known suspected history allergy contradiction mirtazapine folic acid ; 12 . Known currently requirement take mirtazapine folic acid ; 13 . Women pregnant nursing ; 14 . Have previously complete withdrawn study , participate clinical trial another drug within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>mirtazapine</keyword>
	<keyword>folic acid</keyword>
	<keyword>schizophrenia</keyword>
</DOC>